Table of Contents
- Trial overview
- Who participated
- What was studied
- Endpoints and measurements
- Trial design and comparisons
- Key patient points
Trial overview
The Celljuvant study was a Phase 3 interventional trial of A/H1N1 INFLUENZA VACCINE in adults aged 50 years and older.[1] It was completed and enrolled 6,300 participants.[1]
The study focused on immunogenicity, which means how strongly the body makes an immune response after vaccination.[1] It also looked at safety and at whether different vaccine lots behaved the same way.[1]
Who participated
The trial included healthy adults and adults with stable comorbidities.[1] Comorbidities are other health conditions that a person has at the same time as the condition being studied.[1]
These stable conditions were the kind that increase the risk of complications from influenza infection.[1] The study population was specifically older adults, meaning people 50 years and older.[1]
What was studied
The main goal was to show clinical lot-to-lot consistency for three consecutive aQIVc HD lots.[1] This means the researchers wanted to see whether different production lots gave similar immune responses.[1]
The study then compared aQIVc HD with QIVr and aQIV.[1] These comparisons were made for each vaccine strain, including the A/H1N1 strain.[1]
The trial used cell-derived target viruses and a hemagglutination inhibition (HI) assay to measure antibodies.[1] An HI assay is a lab test used to check how well antibodies can block influenza viruses from clumping red blood cells.[1]
Endpoints and measurements
The primary endpoints were measured at Day 29.[1] One endpoint was the Day 29 ratio of geometric mean titer between vaccine lots.[1] GMT is a way to describe the average antibody level in a group.[1]
Another endpoint was immunogenicity of aQIVc HD versus QIVr and aQIV, measured by Day 29 GMT and GMT ratios.[1] The study also measured seroconversion rate from Day 1 to Day 29 and the difference in seroconversion rates between groups.[1]
Seroconversion rate shows the share of people whose antibody levels rise enough after vaccination to count as a clear immune response.[1] These measures were taken for the four vaccine strains in the study.[1]
Trial design and comparisons
The study was designed in a sequential way.[1] First, it checked whether three lots of aQIVc HD were similar in immune response.[1]
Next, it tested whether aQIVc HD was noninferior to QIVr and aQIV.[1] Noninferior means it was not worse than the comparison vaccine by more than a preset amount.[1]
The study compared the vaccines for each strain separately, which helps researchers see how the vaccine performs against A/H1N1 and the other influenza strains included in the trial.[1]
Key patient points
This trial studied older adults because influenza can be more serious in this age group.[1] It also included people with stable health problems if those conditions raised the risk of flu complications.[1]
The main question was not only whether the vaccine caused an immune response, but also whether different batches gave similar results and whether the vaccine compared well with other influenza vaccines.[1] The trial was completed and included a large number of participants, which makes the findings more useful for studying immune response in this population.[1]
